Objective: To investigate miR‑210 expression in astrocyte‑derived extracellular vesicles (ADEVs) from individuals with PD treated with Exenatide versus placebo.

Background: Hypoxic stress profoundly alters neuronal and glial metabolism, initiating enzymatic dysfunction, inflammation, and oxidative injury – processes tightly linked to Parkinson’s disease (PD) pathophysiology. Central to cellular hypoxia adaptation is HIF‑1α, a transcription factor that coordinates metabolic reprogramming and stress‑response pathways. HIF‑1α directly induces miR‑210, while miR‑210 stabilizes and modulates HIF‑1α activity, forming a reciprocal regulatory circuit critical for maintaining cellular resilience. Increasing evidence indicates that GLP‑1 receptor signaling in astrocytes enhances HIF‑1α expression, positioning this pathway as a potential modulator of miR‑210 and astrocyte function under metabolic stress. However, no studies have examined how GLP‑1R activation – such as through Exenatide – affects HIF‑1α–miR‑210 dynamics in human astrocytes or in patients with PD.

Method: We tested a comprehensive pipeline enabling highly specific isolation and molecular profiling of ADEVs from human plasma. Isolation employed a tandem approach integrating size‑exclusion chromatography with GLAST‑targeted immunoaffinity capture. Western blotting confirmed astrocyte specificity, with GLAST enrichment in the captured fraction and CD9 verifying EV integrity. To accommodate the extremely low RNA yield typical of immunocaptured vesicles, we optimized a sensitive qPCR workflow. Systematic inhibition testing identified 1:40 as the optimal cDNA dilution, and stability analysis of candidate endogenous controls identified miR‑16 as the most reliable reference miRNA for ADEV‑based assays.

Results: Using this platform, we quantified miR‑210 across plasma fractions in a proof‑of‑concept analysis. Distribution patterns varied by fraction and miRNA species, underscoring the need for compartment‑resolved profiling rather than bulk plasma measurements.

Conclusion: This workflow provides a valuable platform for future translational studies evaluating ADEV‑associated miRNAs, including hypoxia‑responsive miR‑210, as mechanistically informative biomarkers in Parkinson’s disease.

« Back to 2026 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/astrocyte-derived-extracellular-vesicle-mir-210-expression-in-exenatide-treated-patients-with-parkinsons-disease/